- Home
- THRD vs GHI Comparison
THRD vs GHI Comparison
Compare THRD & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- GHI
- Stock Information
- Founded
- THRD 2019
- GHI 1998
- Country
- THRD United States
- GHI United States
- Employees
- THRD N/A
- GHI N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- GHI Finance: Consumer Services
- Sector
- THRD Health Care
- GHI Finance
- Exchange
- THRD Nasdaq
- GHI Nasdaq
- Market Cap
- THRD 238.7M
- GHI 269.5M
- IPO Year
- THRD 2022
- GHI N/A
- Fundamental
- Price
- THRD $5.42
- GHI $12.12
- Analyst Decision
- THRD Hold
- GHI Strong Buy
- Analyst Count
- THRD 3
- GHI 4
- Target Price
- THRD $5.00
- GHI $16.00
- AVG Volume (30 Days)
- THRD 251.2K
- GHI 42.1K
- Earning Date
- THRD 08-07-2025
- GHI 08-06-2025
- Dividend Yield
- THRD N/A
- GHI 12.13%
- EPS Growth
- THRD N/A
- GHI N/A
- EPS
- THRD N/A
- GHI 0.45
- Revenue
- THRD N/A
- GHI $34,065,322.00
- Revenue This Year
- THRD N/A
- GHI $228.92
- Revenue Next Year
- THRD N/A
- GHI $4.27
- P/E Ratio
- THRD N/A
- GHI $27.26
- Revenue Growth
- THRD N/A
- GHI N/A
- 52 Week Low
- THRD $3.18
- GHI $10.12
- 52 Week High
- THRD $16.02
- GHI $15.31
- Technical
- Relative Strength Index (RSI)
- THRD 68.70
- GHI 56.52
- Support Level
- THRD $5.41
- GHI $11.70
- Resistance Level
- THRD $5.52
- GHI $11.99
- Average True Range (ATR)
- THRD 0.05
- GHI 0.30
- MACD
- THRD -0.01
- GHI 0.02
- Stochastic Oscillator
- THRD 64.29
- GHI 56.25
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.